-
Recent Posts
Recent Comments
Archives
- October 2012
- December 2011
- November 2011
- September 2011
- March 2011
- December 2010
- November 2010
- September 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- November 2009
- October 2009
- September 2009
- July 2009
- June 2009
- February 2009
- January 2009
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- February 2007
- December 2006
- November 2006
- October 2006
- August 2006
- April 2006
- March 2006
- December 2005
- November 2005
- July 2005
- March 2005
- February 2005
- January 2005
- December 2004
- November 2004
- October 2004
- September 2004
- August 2004
Categories
Meta
Monthly Archives: February 2007
Erythropoiesis-stimulating agent (Aranesp)
FDA notified healthcare professionals of the results from a large clinical trial evaluating use of an erythropoiesis-stimulating agent (ESA) to treat anemia in cancer patients not receiving chemotherapy. In this study, patients received either Aranesp, an ESA, according to the … Continue reading
Ranibizumab (Lucentis)
The FDA report and Genentech report on an ongoing study (SAILOR) which confirmed the higher incidence of stroke associated wtih ranibizumab with a 0.5 mg dose group compared to the 0.3 mg dose group (1.2% versus 0.3%, respectively; P=0.02) which … Continue reading
Latest Australian Adverse Drug Reactions Bulletin
The latest edition of the Australian Adverse Drug Reactions Bulletin prepared by ADRAC is out, features include: 1. Traditional Indian (Ayurvedic) and Chinese Medicines associated with heavy metal poisoning 2. Zolpidem and bizarre sleep related effects 3. Increased risk of … Continue reading
Posted in ADRAC
Comments Off